Compare NOG & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NOG | NUVB |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.9B |
| IPO Year | 2000 | N/A |
| Metric | NOG | NUVB |
|---|---|---|
| Price | $27.53 | $5.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 9 |
| Target Price | ★ $29.14 | $11.44 |
| AVG Volume (30 Days) | 1.7M | ★ 4.0M |
| Earning Date | 05-26-2026 | 01-01-0001 |
| Dividend Yield | ★ 6.86% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.39 | N/A |
| Revenue | ★ $2,475,723,000.00 | N/A |
| Revenue This Year | $18.95 | $659.84 |
| Revenue Next Year | N/A | $180.43 |
| P/E Ratio | $23.85 | ★ N/A |
| Revenue Growth | ★ 11.23 | N/A |
| 52 Week Low | $19.88 | $1.57 |
| 52 Week High | $32.62 | $9.75 |
| Indicator | NOG | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 60.94 | 47.60 |
| Support Level | $26.50 | $5.12 |
| Resistance Level | $28.24 | $6.22 |
| Average True Range (ATR) | 1.15 | 0.33 |
| MACD | -0.03 | 0.09 |
| Stochastic Oscillator | 78.41 | 70.95 |
Northern Oil & Gas Inc is an independent energy company engaged in the acquisition, exploration, development, and production of crude oil and natural gas properties. Its principal business is crude oil and natural gas exploration, development, and production. The company's oil and natural gas sales come from three geographic areas in the United States: the Williston Basin (North Dakota and Montana), the Permian Basin (New Mexico and Texas), the Uinta Basin, and the Appalachian Basin (Pennsylvania and Ohio).
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.